Shares of Intellia Therapeutics (NTLA) soared 18.11% during Monday's trading session, outperforming the broader market on optimism over the company's promising drug candidate.
The rally was fueled by a bullish analyst report from JonesTrading on November 13th, which reiterated a Buy rating on NTLA stock. Analyst Debanjana Chatterjee cited promising efficacy and safety data for the company's Nex-Z treatment as the basis for the positive outlook.
Intellia is a leading gene editing company focused on developing curative therapeutics using CRISPR technology. Positive data readouts and analyst support have renewed investor confidence in the company's pipeline and future growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。